Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy.

Diabetes, obesity & metabolism·2014
Same author

What is the best approach to glycaemic control in patients with type 2 diabetes?

Diabetes, obesity & metabolism·2014
Same author

Will the next generation of basal insulins offer clinical advantages?

Diabetes, obesity & metabolism·2013
Same author

Treat-to-target trials: uses, interpretation and review of concepts.

Diabetes, obesity & metabolism·2013
Same author

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents.

Diabetes, obesity & metabolism·2013
Same author

Methods to enhance delivery of prandial insulin and basal-prandial insulin.

Diabetes, obesity & metabolism·2013
Same journal

Relationship Between hsCRP, Glycaemic Control and Response to Sotagliflozin in Type 1 Diabetes: A Post Hoc Analysis of the inTandem3 Trial.

Diabetes, obesity & metabolism·2026
Same journal

Early Weight Regain After GLP-1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De-Escalation Strategies.

Diabetes, obesity & metabolism·2026
Same journal

First-Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial.

Diabetes, obesity & metabolism·2026
Same journal

Trends in Prevalence of Diabetes, Pre-Diabetes, and Cardiometabolic Risk Factor Control Among U.S. Adults, 2013-2023.

Diabetes, obesity & metabolism·2026
Same journal

Metabolic Risk-Attributable Dementia Burden: A Life-Course and Cautious Attribution Perspective.

Diabetes, obesity & metabolism·2026
Same journal

A Highly Powered Large Outcomes Randomised Controlled Trial Will Usually, but Not Always, Have Balanced Groups at Baseline.

Diabetes, obesity & metabolism·2026
See all related articles

Related Experiment Videos

Current challenges in type 2 diabetes

A J Garber1

  • 1Division of Endocrinology, Diabetes and Metabolism Baylor College of Medicine Houston, TX 77030, USA. agarber@bcm.tmc.edu

Diabetes, Obesity & Metabolism
|March 13, 2012
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos